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Preeclampsia is a syndrome with diverse clinical presentation that currently has no cure. The apelin 
receptor system is a pleiotropic pathway with a potential for therapeutic targeting in preeclampsia. We 
established the systemic outcomes of (Pyr1)-apelin-13 administration in rats with preeclamptic features 
(TGA-PE, female transgenic for human angiotensinogen mated to male transgenic for human renin). 
(pyr1)-apelin-13 (2 mg/kg/day) or saline was infused in TGA-PE rats via osmotic minipumps starting at 
day 13 of gestation (GD). At GD20, TGA-PE rats had higher blood pressure, proteinuria, lower maternal 
and pup weights, lower pup number, renal injury, and a larger heart compared to a control group 
(pregnant Sprague-Dawley rats administered vehicle). (Pyr1)-apelin-13 did not affect maternal or fetal 
weights in TGA-PE. The administration of (Pyr1)-apelin-13 reduced blood pressure, and normalized 
heart rate variability and baroreflex sensitivity in TGA-PE rats compared to controls. (Pyr1)-apelin-13 
increased ejection fraction in TGA-PE rats. (Pyr1)-apelin-13 normalized proteinuria in association 
with lower renal cortical collagen deposition, improved renal pathology and lower immunostaining 
of oxidative stress markers (4-HNE and NOX-4) in TGA-PE. This study demonstrates improved 
hemodynamic responses and renal injury without fetal toxicity following apelin administration 
suggesting a role for apelin in the regulation of maternal outcomes in preeclampsia.
Preeclampsia is a multisystem syndrome characterized by a new onset hypertension and end-organ dysfunc-
tion with or without proteinuria1. It is associated with high maternal morbidity, premature birth, and intrauter-
ine growth restriction. Women and children exposed to preeclampsia are more likely to develop cardiovascular 
disease later in life2. The prevalence and incidence of preeclampsia continue to increase in the United States3,4. 
However the pathogenesis of preeclampsia is still not well understood and treatment options remain very limited.
Apelin is a novel peptide with demonstrated beneficial cardiovascular effects in animal and human stud-
ies. Apelin exerts blood-pressure-lowering5–8, inotropic9, anti-apoptotic10, and pro-angiogenic effects11. Apelin 
acts on a G-protein-coupled receptor, apelin receptor (APJ). Several peptides are formed from the apelin pre-
cursor, and all apelin forms exert their effects through APJ signaling. Furthermore, pyroglutamate apelin-13 
((Pyr1)-apelin-13) is a posttranslationally modified form of apelin-13 containing the pyroglutamate group at the 
NH2 terminus of the peptide. We and others have demonstrated that apelin and APJ are expressed in human 
normal and preeclamptic placenta in syncytiotrophoblasts, cytotrophoblasts, and endothelial cells of fetal cap-
illaries12–14. Apelin and APJ have similar distribution in human placenta, suggesting a paracrine effect of apelin 
receptor system. Using a quantitative radioimmunoassay, we have previously reported that total apelin content 
is lower in human preeclamptic chorionic villi suggesting reduced influence on regulation of the fetal-maternal 
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interface12. We also demonstrated a complex profile and different patterns of apelin forms in human preeclamptic 
versus normal chorionic villi12. However, circulating levels of apelin were lower15, not different16, or higher17 in 
women with preeclampsia compared with women with normal pregnancy, probably reflecting different patient 
populations and assay conditions. Importantly, levels of apelin in maternal circulation correlate with levels of 
apelin in fetal plasma18 suggesting a reciprocal regulation of this peptide in mother and baby. In short, the levels 
and the distribution patterns of apelin and its receptor in human placenta suggest a potential of this peptide for 
therapeutic targeting in preeclampsia.
Since the systemic effects of exogenously administered apelin in preeclampsia are not well described, the 
goal of this study was to determine the effects of a systemically administrated and more stable form of apelin, 
(Pyr1)-apelin-13, on maternal and fetal characteristics, and cardiovascular and renal outcomes in an established 
rat model with preeclamptic features (TGA-PE, female transgenic for human angiotensinogen mated to male 
transgenic for human renin). This model was chosen based on the following characteristics: lower circulating 
levels of apelin, the expression of many features of human preeclampsia such as increased blood pressure at late 
pregnancy, intrauterine growth restriction, proteinuria, increased circulating sFlt and vasopressin, the presence of 
circulating agonistic antibodies to angiotensin II receptor 1, and glomerular endotheliosis versus Sprague Dawley 
rats (controls), and good reproducibility19–21.
Results
Maternal and Fetal Characteristics in TGA-PE versus SD rat. Table 1 shows that at the GD20, 
TGA-PE rats had lower maternal and pup weight, and number of pups compared with SD rats. There were no dif-
ferences in placental weight or fetal-to-placental weight ratio. There were two pup resorptions noted in TGA-PE 
rats versus none noted in SD groups. In addition, heart-to-maternal body weight was higher in TGA-PE rats com-
pared with controls. Water intake increased in TGA-PE versus SD females as did urine volume, but the differences 
were not statistically significant. There were no alterations in food intake.
effects of (pyr1)-apelin-13 on Maternal and Fetal Characteristics, Blood Pressure, and 
Sympathovagal Activity. Serum levels of apelin were lower in TGA-PE compared with SD rats. Apelin 
infusion increased serum apelin in SD and TGA-PE rats compared with respective vehicle controls (Table 1). 
(Pyr1)-apelin-13 had no effect on maternal or fetal weight, pup number or length, or placental weight in TGA-PE 
or SD compared with respective controls. TGA-PE rats had higher mean and systolic blood pressures compared 
with SD rats (Fig. 1). (Pyr1)-apelin-13 reduced systolic and mean blood pressure in TGA-PE rats with no effect in 
SD rats. Diastolic blood pressure was higher in TGA-PE versus SD rats; however, the administration of the pep-
tide did not change diastolic blood pressures. TGA-PE had increased heart rate that was normalized by the treat-
ment with (Pyr1)-apelin-13 (Fig. 2A). TGA-PE rats also had impaired heart rate variability (HRV) (measured as 
root of mean successive differences [rMSSD]) compared with SD controls (Fig. 2B). Apelin treatment normalized 
HRV in TGA-PE rats with no change in SD rats. Similarly, baroreflex sensitivity (BRS) measured in the sequence 
domain was lower in TGA-PE versus SD and was normalized with (Pyr1)-apelin-13 (Fig. 2C).
Effects of (Pyr1)-apelin-13 Administration on Systemic Markers of Preeclampsia. Because preec-
lampsia is associated with higher levels of sFlt-1 and vasopressin, we tested the effects of systemic (Pyr1)-apelin-13 
administration on these circulating markers. Plasma sFlt-1 and vasopressin were higher in TGA-PE rats versus 
untreated SD females at GD20. (Pyr1)-apelin-13 administration had no effect on these parameters (Fig. 3A,B). 
(Pyr1)-apelin-13 also had no effect on maternal serum leptin or hematocrit (Fig. 3C,D).
Cardiac Effects of (Pyr1)-apelin-13. Since heart weight was greater in TGA-PE rats, we explored whether 
preeclampsia altered systolic function and whether (Pyr1)-apelin-13 had affected ejection fraction, stroke volume, 
SD SD + (Pyr1) TGA-PE TGA-PE + (Pyr1)
Maternal Weight, g 0.348 ± 0.01 0.377 ± 0.006 0.303 ± 0.009* 0.301 ± 0.007*
Pup Weight, g 3.68 ± 0.1 3.85 ± 0.11 3.21 ± 0.1* 3.17 ± 0.1*
Pup Length, cm 3.5 ± 0.03 3.7 ± 0.09 3.1 ± 0.15* 3.2 ± 0.09^
Number of Pups 14.5 ± 0.8 14.5 ± 0.6 10.7 ± 1.1* 12.7 ± 0.5
Placental Weight, g 0.45 ± 0.01 0.54 ± 0.02 0.41 ± 0.02 0.42 ± 0.01
Fetal/Placental Weight Ratio 8.10 ± 0.25 7.26 ± 0.31 7.90 ± 0.27 7.80 ± 0.28
Pup Resorption, Number 0 0 2 0
Maternal Total Kidney Weight/Body Weight, g 0.85 ± 0.03 0.95 ± 0.02 0.84 ± 0.02 0.84 ± 0.02
Maternal Heart Weight/Body Weight, g 0.80 ± 0.02 0.74 ± 0.01 1.17 ± 0.11* 1.04 ± 0.02
Food Intake, g 20.13 ± 2.2 20.5 ± 0.54 18.5 ± 1.55 16.45 ± 2.56
Water Intake, ml 37.11 ± 4.48 64.26 ± 15.96 55.47 ± 6.64* 45.45 ± 7.30
Urine Volume, ml 13.53 ± 2.25 7.66 ± 0.59 26.22 ± 6.25 37.52 ± 9.17*^
Serum Total Apelin Levels, ng/ml 1.6 ± 0.1 2.4 ± 0.1* 1.2 ± 0.10* 1.7 ± 0.10#^
Table 1. Maternal and Fetal Characteristics in Pregnant Sprague-Dawley (SD) and Transgenic Rats with 
Preeclamptic Features (TGA-PE) at Day 20 of Gestation. Data are mean ± SEM, *p < 0.05 vs. SD; #p < 0.5 vs. 
TGA-PE, ^p < 0.05 vs. SD-(Pyr1), n = 5–8.
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cardiac output, or relative posterior wall thickness. TGA-PE rats had lower ejection fraction compared with SD 
rats. No significant differences in other indices of cardiac function were observed between SD and TGA-PE 
groups (Table 2). (Pyr1)-apelin-13 increased ejection fraction in TGA-PE females. There were no differences in 
stroke volume, cardiac output, or relative posterior wall thickness in TGA-PE rats treated with (Pyr1)-apelin-13 
compared with SD females (Table 2).
Renal Effects of (Pyr1)-apelin-13. Proteinuria was greater in TGA-PE rats, and was normalized by 
(Pyr1)-apelin-13 administration (Fig. 4A). (Pyr1)-apelin-13 also reduced renal cortical collagen content in 
these rats (Fig. 4B,C). TGA-PE females had higher incidence of pathological changes of various degrees includ-
ing greater injury scores for renal interstitial fibrosis, glomerulosclerosis, and VSMC hyperplasia (Table 3). 
(Pyr1)-apelin-13 administration reduced glomerulosclerosis and interstitial fibrosis, while no differences were 
found in injury scores for other markers between TGA-PE treated with apelin compared with TGA-PE con-
trol (Table 3). Figure 5 demonstrates fractional distribution of renal injury scores in SD, TGA-PE, and TGA-PE 
treated with (Pyr1)-apelin-13. In addition, the markers of oxidative stress NOX4 and 4-HNE were greater in 
TGA-PE, but were reduced following administration of (Pyr1)-apelin-13 in TGA-PE rats (Fig. 6).
Discussion
As defined by the recent recommendations of the American College of Obstetricians and Gynecologists, preec-
lampsia is a multisystem syndrome characterized by hypertension accompanied by thrombocytopenia, impaired 
liver function, development of new renal insufficiency, pulmonary edema, or new-onset cerebral or visual dis-
turbances1. Many advances have been made in the past decade in establishing the mechanisms of preeclampsia; 
however, no specific therapies are available for the treatment of this disorder. Considering the complicated nature 
of preeclampsia, therapeutic agents that act on multiple systems may provide the most efficacious treatment. Our 
study reports the therapeutic effectiveness of apelin administration in rats with preeclamptic features. We show 
that apelin reduces blood pressure in addition to improving parasympathetic tone, proteinuria, renal damage, and 
renal oxidative stress without toxic effects on maternal or fetal weight. Our findings suggest that (Pyr1)-apelin-13 
may be beneficial for the treatment of preeclampsia due to its hemodynamic and reno-protective effects. We also 
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Figure 1. The effects of (Pyr1)-apelin-13 on systolic (A), diastolic (B), and mean (C) blood pressures in 
TGA-PE and SD rats at day 20 of gestation. Data are mean ± SEM. *p < 0.05 vs. SD saline-treated; #p < 0.05 vs. 
TGA-PE saline-treated; n = 5–7.
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report for the first time that the hypotensive effect of (Pyr1)-apelin-13 may involve central control of the cardio-
vascular system.
An established transgenic model of pregnancy with preeclamptic features was used in this study (TGA-PE). 
The advantages of this model are the development of many features of human preeclampsia as well as good 
reproducibility. Moreover, the plasma levels of apelin are lower in TGA-PE rats versus normal pregnant SD rats 
suggesting the downregulation of circulating apelin system. Similar to other studies using this model, blood pres-
sure and proteinuria were significantly increased in pregnant transgenic rats19–21. We also report for the first time 
that the levels of circulating sFlt and vasopressin were greater in TGA-PE rats compared with normal pregnant 
rats. Since the placenta has many proteases and other protein-degrading enzymes, we chose to use a more stable 
to degradation form of apelin, (Pyr1)-apelin-13, at a dose that previously was shown to be effective in reducing 
blood pressure5.
Apelin has anti-hypertensive effects in humans and animal models when administered systemically5,22–26. The 
effectiveness of apelin’s blood pressure-lowering effects depends on several factors, including the dose, anesthesia, 
route of administration, and experimental model27. In addition, apelin receptor conformational states stabilized 
by the binding of different apelin fragments may also influence the hypotensive effects of apelin26. Our data agree 
with other reports5,22–26 showing blood pressure lowering effects of (Pyr1)-apelin-13 when it is administered sys-
temically in the peripheral vascular system. Apelin can increase the levels of a major vasodilator in the circulation 
- nitric oxide28 or nitric oxide bioavailability, and therefore improve endothelial function and reduce vascular 
resistance5. Although not measured in our study, lower overall total peripheral resistance may lead to the reduc-
tion in blood pressure in response to apelin treatment.
Autonomic nervous system plays an important role in the adaptations of cardiovascular system to pregnancy. 
The activity of sympathetic and parasympathetic tone can be measured non-invasively using the spectral analysis 
method of time and frequency domains. Pregnancy lowers baroreflex sensitivity and sympathetic activity that 
may in part be responsible for orthostatic hypotension experienced by pregnant women29. Preeclampsia further 
impairs the baroreflex sensitivity30. In agreement with human studies, we report for the first time that pregnant 
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Figure 2. The effects of (Pyr1)-apelin-13 on heart rate (A), heart rate variability (B), and baroreflex sensitivity 
(C) in TGA-PE rats at day 20 of gestation. Data are mean ± SEM. *p < 0.05 vs. SD saline-treated; #p < 0.05 vs. 
TGA-PE saline-treated; n = 5–7. Abbreviations: HR, heart rate; BRS, baroreflex sensitivity.
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transgenic rats develop lower parasympathetic tone at the end of pregnancy. Apelin treatment reversed this effect 
indicating the improvement of central nervous system regulation contributing to the blood pressure-lowering 
effects of apelin in preeclamptic rats. Moreover, lower baroreflex sensitivity29, has been linked to altered insulin 
sensitivity31. Future studies will explore links between baroreflex sensitivity, blood pressure, insulin sensitivity, 
and the apelin receptor system.
(Pyr1)-apelin-13 given from GD13 to GD20 had no effect on maternal or fetal weight, suggesting that the 
peptide had no overall toxicity during mid-late pregnancy. Maternal weight can determine fetal weight; therefore, 
the absence of changes in fetal weight may in part be explained by the absence of changes in maternal weight. 
In addition, no changes in food intake or leptin levels were found at the end of pregnancy in preeclamptic rats. 
Leptin is a hormone produced by adipose cells. Maternal circulating levels of leptin are increased in human and 
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Figure 3. Circulating markers (sFlt-1, (A); Vasopressin, (B); Leptin, (C); Hematocrit, (D) in response to (Pyr1)-
apelin-13 administration in TGA-PE rats at day 20 of gestation. Data are mean ± SEM. *p < 0.05 vs. SD saline-
treated; n = 7–8.
SD TGA-PE TGA-PE + (Pyr1)
Stroke volume, ml 171.2 ± 21.5 155.9 ± 19.2 180.5 ± 20.9
Cardiac Output, ml/min 54.1 ± 7.2 48.1 ± 7.3 56.1 ± 5.5
Ejection Fraction, % 88.9 ± 2.9 79.7 ± 2.4* 90.5 ± 0.6#
Relative PW Thickness 0.57 ± 0.06 0.56 ± 0.04 0.73 ± 0.08
Table 2. Cardiac Function in Response to (Pyr1)-Apelin-13 Administration in Transgenic Rats with 
Preeclamptic Features (TGA-PE) at Day 20 of Gestation. Data are mean ± SEM, *p < 0.05 vs. SD; #p < 0.05 vs. 
TGA-PE, n = 4–5.
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rat pregnancy compared with the non-pregnant state32. We found no differences in leptin levels in preeclamptic 
versus untreated SD rats and no effect of (Pyr1)-apelin-13 on leptin levels, suggesting no interaction between 
apelin and leptin in our model.
Previous studies demonstrated higher circulating levels of pro-angiogenic marker sFlt-133 or anti-diuretic 
hormone vasopressin34 in women with preeclampsia compared with healthy controls. Apelin can mediate angi-
ogenesis via upregulation of vascular endothelial growth factor (VEGF) or VEGF receptor 235. Apelin can also 
counteract vasopressin actions by reducing plasma arginine vasopressin (AVP) levels in lactating rats or by induc-
ing the direct effects on aquaporin 2 insertion at the apical membrane of collecting duct36,37. However, in our 
study, (Pyr1)-apelin-13 had no effect on sFlt-1 or vasopressin measured at the end of pregnancy in TGA-PE rats. 
Consistent with no changes in vasopressin with apelin treatment, urine volume was not significantly changed. 
Since the current view of preeclampsia emphasizes different underlying mechanisms leading to a multisystemic 
syndrome38, it is possible that apelin’s actions in our study were mediated by pathways independent of or down-
stream from sFlt-1 or vasopressin.
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Figure 4. Renal proteinuria (A) and collagen deposition (B,C) in response to (Pyr1)-apelin-13 administration 
in TGA-PE rats at day 20 of gestation. Data are mean ± SEM. *p < 0.05 vs. SD saline-treated; #p < 0.05 vs. 
TGA-PE saline-treated; n = 5–6.
SD SD SD TGA-PE
TGA-
PE TGA-PE
TGA-PE-
(Pyr1)
TGA-PE-
(Pyr1)
TGA-PE-
(Pyr1)
Pathologic Findings A B C A B C A B C
Interstitial Fibrosis 0.4 ± 0.2 40 16 ± 9.7 2.5 ± 0.2 100 250 ± 22.3* 1.7 ± 0.2 100 150 ± 18.3#
Glomerulosclerosis 0.6 ± 0.2 60 36 ± 14.7 2.1 ± 0.4 100 129.8 ± 29.7* 1.1 ± 0.1 100 57.1 ± 4.8#
VSMC Hyperplasia 0 0 0 1.75 ± 0.1 100 175 ± 17.1* 1.5 ± 0.2 100 150 ± 18.9*
Tubular Casts 0.2 ± 0.2 20 4 ± 4 1 ± 0.6 33.3 33.3 ± 21.1 1 ± 0.4 57.1 57.1 ± 24.9
Table 3. The Effect of (Pyr1)-apelin-13 Administration on Renal Pathology at Day 20 of Gestation. 
Abbreviations: A – Severity, B – Incidence, C- Score. SD, Sprague-Dawley, TGA-PE, preeclamptic rat, TGA-PE-
(Pyr1), preeclamptic rat treated with (Pyr1)-apelin-13. Each lesion was given a grade using a 5-point grading 
scale: 1 = minimal, 2 = mild, 3 = moderate, 4 = marked, 5 = severe. Injury scores are calculated as a product of 
a lesion’s severity grade and the incidence. The data are mean ± SEM, *p < 0.05 vs. SD, #p < 0.05 vs. TGA-PE, 
n = 5–7.
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Apelin has strong inotropic effect in animal studies, including isolated heart preparations, myocardial trabec-
ulae, and single cardiomyocytes9,39,40. Increased myocardial contractility partly depends on increased intracellular 
calcium levels or activation of inositol triphosphate receptor40,41. In addition, apelin administration improved car-
diac contractility, and reduced infarct size in experimental models of myocardial infarction28,42–45. We found that 
heart weight was greater in TGA-PE rats compared with normal pregnant rats. To establish whether increased 
heart weight was accompanied with impaired cardiac function in TGA-PE rats, we determined ejection frac-
tion. Although ejection fraction was lower in TGA-PE compared with normal pregnant rats, these values were 
within normal limits of this parameter in rats. A recent study reported no differences in ejection fraction in 
women with preeclampsia compared with women with normal pregnancy, however more detailed analysis using 
myocardial strain imaging with speckle tracking revealed worsened strain in preeclamptic women46. It is pos-
sible that TGA-PE rats have changes in the heart that can only be detected using more sensitive methods than 
analyzing ejection fraction. Our study showed increased systolic cardiac function in preeclamptic rats following 
(Pyr1)-apelin-13 administration as was evident by increased ejection fraction in agreement with other reports 
demonstrating inotropic effect of apelin. We further evaluated cardiac function in TGA-PE rats by examining car-
diac output. Pregnancy increases cardiac output, stroke volume and heart rate to accommodate for higher blood 
 Renal Injury Scores
SD
TG
A-
PE
TG
A-
PE
-(P
yr1
)
0
200
400
600
800
Interstitial Fibrosis
Glomerulosclerosis
VSMC Hyperplasia
Tubular Casts
In
ju
ry
Sc
or
e
(P
ro
du
ct
of
Se
ve
rit
y
an
d
In
ci
de
nc
e)
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apelin-13. Data are illustrated by treatment group.
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Figure 6. Renal NOX4 (A) and 4-HNE (B) in response to (Pyr1)-apelin-13 administration in TGA-PE rats at 
day 20 of gestation. Data are mean ± SEM. *p < 0.05 vs. SD, #p < 0.05 vs. TGA-PE saline-treated; n = 4–5.
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volume associated with healthy pregnancy47. Cardiac output was not different between preeclamptic and normal 
pregnant rats. Although cardiac output was higher in TGA-PE treated with apelin compared with TGA-PE, it did 
not reach statistical significance, perhaps due to a small sample size. Higher cardiac output in addition to lower 
blood pressure in TGA-PE rats treated with apelin could suggest decreased total peripheral resistance. Overall, 
TGA-PE rats have suboptimal cardiovascular adaptations to pregnancy with preserved ejection fraction. In agree-
ment with other studies, apelin administration positively modulated systolic cardiac function in TGA-PE rats.
Furthermore, preeclampsia can be associated with proteinuria, glomerular and tubular changes48,49. Apelin 
treatment attenuated glomerulosclerosis and interstitial fibrosis in agreement with reduced total renal collagen 
deposition in TGA-PE rats. These histological changes were associated with the reduction in oxidative stress 
markers. Lower glomerulosclerosis may in part be explained by the improvement of renal hemodynamics since 
apelin had been shown to induce vasorelaxation of angiotensin II-preconstricted efferent and afferent arteri-
oles36. However, apelin did not have a significant effect on VSMC hyperplasia or tubular casts in TGA-PE rats. 
Short-term treatment with apelin may not be enough to reverse all damage in the kidney and other mechanisms 
that were not influenced by apelin could be responsible for vascular damage in the kidney of rats with preeclamp-
tic features. Further studies are warranted on investigating the mechanisms of apelin actions in the kidney in 
preeclampsia. Overall, apelin improved renal pathology in addition to lowering oxidative stress markers, suggest-
ing that (Pyr1)-apelin-13 may provide reno-protection in preeclampsia.
Perspectives. Preeclampsia is a complex multifactorial syndrome that currently has no cure. Our study 
opens the possibility of considering apelin as an important mediator of hemodynamic and renal pathophysiol-
ogy in preeclampsia due to its blood pressure-lowering and reno-protective effects. Future studies are needed to 
investigate the tissue-specific mechanisms of apelin’s actions in preeclampsia.
Materials and Methods
Animals. The study was approved by the Institutional Animal Care and Use Committee of the Wake Forest 
School of Medicine (A14-163), and all experiments and methods were performed in accordance with relevant 
guidelines and regulations. Female transgenic rats with overexpression of human angiotensinogen (TGA) or male 
transgenic rats with overexpression of human renin (TGR) were obtained from the colony maintained by the 
Department of Surgery/Hypertension and Vascular Research, Wake Forest School of Medicine. Sprague-Dawley 
(SD) rats purchased from Charles River Laboratories (Wilmington, MA, USA) were used in control experiments. 
All rats were housed at a constant room temperature, humidity, and light cycle (12:12-h light-dark), fed a standard 
rodent chow (Lab Diet 5P00 - Prolab RMH 3000, PMI Nutrition International, INC, Brentwood, MO) and given 
water ad libitum throughout the experimental protocols.
Study timeline. Female TGA rats were mated to male TGR rats to develop preeclamptic features (TGA-PE). 
SD females were bred to SD male rats. First time pregnant TGA-PE and SD rats at 10–15 weeks of age were 
used for this study. Day 0 of pregnancy was established by the presence of a vaginal plug or sperm in the vaginal 
smear. (Pyr1)-apelin-13 (2 mg/kg/day)5 (American Peptide, Sunnyvale, VA) or saline was infused subcutaneously 
in TGA-PE or SD female rats via osmotic minipumps (model 2ML4; Alzet Osmotic Pumps, Cupertino, CA) 
starting at day 13 of gestation (GD13). Cardiac echocardiography was done in all rats at GD19 using a Vevo LAZR 
Ultrasound and Photoacoustic System (FujiFilm, VisualSonics, Toronto, Canada). On the evening of GD19, ani-
mals were placed in metabolic cages for 24-hour collection of urine (MMC 100, Hatteras Instruments, Cary, NC). 
Blood pressures were taken in the morning of the following day and rats were sacrificed in the afternoon of GD20.
Blood pressure recordings. Systolic, diastolic, and mean blood pressures were recorded using an 
intra-arterial catheter placed into the left femoral artery under 2.5% isoflurane anesthesia. Blood pressure signals 
were acquired for 10 minutes using PowerLab equipment (ADInstruments, Colorado Springs, CO) and analyzed 
by LabChart software. Heart rate was also calculated from this recording as beats per minute. Data were averaged 
for each animal and reported as mean ± SEM.
Heart rate variability and baroreflex measurements. Indices of sympathovagal activity were calcu-
lated by spectral analysis of the time and frequency domains using software designed for rats (Nevrokard SA‐BRS, 
Nevrokard Kiauta, Izola, Slovenia), as previously described50,51. Spontaneous baroreflex sensitivity (BRS) was 
determined from a minimum of 10 min of arterial blood pressure recordings and was calculated in the time 
domain as Sequence ALL (Seq ALL; in units of milliseconds per mmHg). Time‐domain analysis was used to cal-
culate measures of heart rate variability (HRV), an index of cardiac vagal tone, measured in milliseconds as root 
of mean square of successive differences (rMSSD).
Ultrasound measurements. Animals were placed on a temperature controlled platform. Chest hair was 
removed using a depilatory cream (Nair, Church & Dwight Co., Inc). Echocardiography was performed using 
a Vevo LAZR Ultrasound and Photoacoustic System and MS250S transducer under 1.5% isoflurane anesthe-
sia. Heart rate was determined from 5 consecutive RR intervals using ECG electrodes connected to a temper-
ature controlled platform. Left ventricle M-mode images were recorded in the short-axis parasternal view. The 
ejection fraction (EF) was calculated as %EF = ((left ventricle end-diastolic volume (LVEDV) − left ventricu-
lar end-systolic volume (LVESV)/LVEDV) × 100. The relative wall thickness was calculated as (posterior wall 
thickness in diastole (PWTd) + anterior wall thickness in diastole (AWTd)/left ventricular end-diastolic diameter 
(LVEDD). Stroke volume (SV) was determined as SV = (EDV − ESV) µl. Cardiac output (CO) was determined as 
cardiac output (CO) = heart rate (HR) × SV/1000 ml/min.
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Enzyme immunoassay (EIA) for circulating apelin. Apelin-12 extraction free Enzyme immunoassay 
kit (EIA), protocol 2 (Phoenix Pharmaceuticals, Inc., Burlingame, CA) was used to measure serum levels of apelin 
in SD and TGA-PE rats. This assay recognizes all forms of apelin and measures total apelin levels.
Sirius Red collagen staining. Paraffin-embedded kidney sections (5μm) were stained with standard Sirius 
Red staining to identify collagen content using reagents from Sigma-Aldrich (St. Louis, MO). Sections were 
incubated in 0.1% Picro-Sirius Red solution followed by 0.5% Glacial Acetic acid. Slides were scanned with a 
Hamamatsu Nanozoomer 2.0 HT utilizing NDP.scan and NDP.view as the imaging software at 20X magnifica-
tion (Hamamatsu). The total area of collagen deposition (red staining) was identified in 12 sections of the digi-
tized images from each kidney (n = 6–7) and measured as the collagen-to-field ratio using Adobe Photoshop 7.0. 
Analyses were performed by an investigator blinded to the experimental groups.
Injury scores were determined using Sirius Red Collagen staining. The following criteria were used 
to identify renal injury as previously described by us52,53: for glomerulosclerosis - increased collagen deposi-
tion within the glomerular or periglomerular area; for vascular smooth muscle cell hyperplasia – changes in the 
cellularity/organization of layers observed in arteries; for interstitial fibrosis - an increased amount of collagen 
between tubules; greater degrees of fibrosis were graded higher if more parenchyma was involved; for tubular 
casts – presence of cast within the tubule. Each lesion was given a grade using a 5-point grading scale: grade 
1 = minimal, grade 2 = mild, grade 3 = moderate, grade 4 = marked, grade 5 = severe. The data are reported as 
injury scores calculated as a product of a lesion’s severity grade and the incidence.
Immunohistochemistry. Kidney tissues were fixed in formalin and 70% ethanol, embedded in paraffin 
and cut into 5-µm sections. Immunostaining was performed using the avidin biotin complex (ABC) method 
with 0.1% diaminobenzene solution used as the chromogen as previously described52,53. Antigen retrieval treat-
ment with sodium citrate buffer (pH 6.0) was applied at 90–95 °C for 30 min. Non-specific binding was blocked 
in a buffer containing 10% normal goat serum, 1% Triton-X in PBS for 30 min. Kidney sections were incubated 
with the rabbit polyclonal 4-hydroxy-2-nonenal Michael Adducts (4-HNE; dilution: 1:10,000; Calbiochem, La 
Jolla, CA), rabbit polyclonal NOX-4 antibody (dilution: 1:200; Proteintech, Rosemont, IL, USA) and secondary 
biotinylated goat anti-rabbit antibody (dilution: 1:400; Vector Laboratories, Burlingame, CA, USA). Slides were 
scanned with a Hamamatsu Nanozoomer 2.0 HT utilizing NDP.scan and NDP.view as the imaging software at 
0.25 and 20X magnification. Images of 4-HNE or NOX-4 staining were analyzed using Adobe Photoshop 7.0 in 
9 sections from each kidney cortex (n = 4–5) by an investigator blinded to the experimental groups and the data 
are reported as relative intensity units.
Statistics. All data were tested for normality. Groups were compared using two-way analysis of variance 
(ANOVA) or one-way ANOVA followed by the Bonferroni’s post-tests (GraphPad Software, San Diego, CA). A 
p value less than 0.05 was considered statistically significantly different. All data were presented as mean ± SEM.
Data Availability
Data is available from the authors upon reasonable request.
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